[1] Forgione MO,McClure BJ,Yeung DT,et al.MLLT10 rearranged acute leukemia:Incidence,prognosis,and possible therapeutic strategies[J].Genes Chromosomes Cancer,2020,59(12):709-721.
[2] 胡德媛,沈凯,郭虞莎,等.PICAML-MLLT10融合基因阳性急性髓系白血病4例报告并文献复习[J].中华血液学杂志,2023,44(8):687-689.
[3] 鲁淑婷,姚金红,李少阳,等.伴PICALM-MLLT10的急性非淋巴细胞白血病2例报告并文献复习[J].重庆医学.2021,50(19):3369-3374.
[4] Park MS,Kim HY,Lee JJ,et al.The first case of acute myeloid leukemia with t(10;11) (p13;q21); PICALM-MLLT10 rearrangement presenting with extensive skin involvement[J].Ann Lab Med,2023,43(3):310-314.
[5] Borel C,Dastugue N,Cances-Lauwers V,et al.PICALM-MLLT10 acute myeloid leukemia:a French cohort of 18 patients[J].Leuk Res,2012,36(11):1365-1369.
[6] Wang J,Zhang W,Xu X,et al.Clinicopathologic features and outcomes of acute leukemia harboring PICALM::MLLT10 fusion[J].Hum Pathol,2024(151):105626.
[7] Sun H,Zhu Y,Li J,et al.PICALM::MLLT10 may indicate a new subgroup of acute leukemias with miscellaneous immunophenotype and poor initial treatment response but showing sensitivity to venetoclax[J].E Haem,2024,5(3):565-572. |
2025, Vol. 31 
